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摘   要 
 









β1 亚基是 20S 催化亚复合体中的一个具有类 Caspase 酶活的亚基，分子量为
23 kDa。发表在 ABB 杂志上的一篇文献报道称当细胞周期运转时 β1 亚基的活性
提高，而蛋白酶体的 β1、β2、β5 亚基细胞内含量水平并没有发生相应的变化。这
说明 β1 亚基可能在细胞周期运转、细胞增殖中起作用。 
为了深入地研究 β1 亚基的细胞生物学功能，我们首先构建了 pDsRed1-C1-β1




































The Ubiquitin-proteasome pathway (UPP) is an important pathway for 
intracellular protein selective degradation,it executes a cascade reaction for degration 
of targeted protein.The function and level of the multitude of proteins are regulated by 
this pathway in eucaryotic cell. The 26S proteasome is a multicatalytic protease found 
in both the cytosol and the nucleus. In the normal eucaryotic cell, it is a large 
multisubunit complex containing two subcomplexes: the 20S proteasome—the 
proteolytic core and the 19S particle, a regulatory complex required for the 
recognition of ubiquitinylated proteins and their preparation for degradation. The 26S 
proteasome has great influence on cell cycle, the action of transcription factor, 
proliferation and apoptosis and other physiological process. 
β1 is a subunit of 20S subcomplex, which has caspase-like activity，its molecular 
weight is 23kDa. In the year of 2007,an article from Archives of Biochemistry and 
Biophysics reports that the activity of the β1 subunit is up-regulated as cells enter the 
cell cycle without concomitant change in the levels of the proteasome β1，β2，β5 
subunits. So we estimated that β1 involves in the cell growth, proliferation and 
apoptosis. 
To further study the biological function of β1 subunit, I constructed 
pDsRed1-C1-β1 plasmid and its mutants at first, and then I transfect corresponding 
plasmid into HeLa cell line transiently and select stably transfected cells with 
antibiotic G418. These stable cell lines will become the foundation of the further study 
in future. 
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泛素链标签的蛋白质传送至 26S 蛋白酶体进行降解[5, 6]。经蛋白酶体降解后的
产物为 8—12 个氨基酸的多肽[8]。  





酶体选择性地降解成短肽[9]。主要过程：Ub 首先被 Ub 活化酶（ubiquitin activating 
enzymes，E1）活化，Ub 上的 Gly 与 E1 上的半胱氨酸 Cys 残基形成高能硫酯键
而连接在一起，然后通过转酯作用，Ub 从 E1 转移到 Ub 结合酶（ubiquitin 
conjugating enzymes，E2）上的半胱氨酸 Cys，活化的 Ub 再从 E2 转移到底物特















过形成底物-E3 复合物（substrate-E3 complex），使底物发生泛素化，即多个 Ub
分子通过异肽键（isopeptide bond）结合在靶蛋白的赖氨酸 lys 上，形成多聚 Ub
链，并以此作为水解信号被 26S 蛋白酶体识别，进入从而被降解[2, 10] （图 1.1）。 




现在发现的泛素连接酶（E3）主要有三大类：HECT(homologous to E6-AP 
carboxyl terminus)结构域家族和RING(the really interesting new gene)结构域家族和
U-box 结构域家族。HECT 结构域家族成员直接催化泛素连接到底物蛋白质上，
其代表性成员包括 E6-AP 和 Nedd4 等。RING 结构域家族分为两种类型：（1）单
独一种成分起作用，该类主要为 N-识别蛋白连接酶，此类连接酶选择蛋白进行降
解基于这些蛋白的 N 末端残基，成员包括 CBL and IAPs 等（2）多成分复合体：
该类型成员 多的为 SCF 家族。以上连接酶中 RING 结构域家族和 U-box 结构域































图 1.1 泛素-蛋白酶体降解途径简图[12] 
 Fig 1.1 Overview of the ubiquitin–proteasome pathway (UPP) 
 
1.1.2 26S 蛋白酶体 
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